By Kevin Conroy, Medium
When President Nixon signed the National Cancer Act, the goal was clear: a national commitment to cure cancer. And while major progress has been made during the last half century, cancer remains a leading cause of death. That’s why the Administration’s new national effort — the Cancer Moonshot — has left many wondering if significant progress is realistic.
The Cancer Moonshot goal of making a decade’s worth of progress in cancer prevention, diagnosis, treatment and care in five years is both audacious and achievable.
The Cancer Moonshot goal of making a decade’s worth of progress in cancer prevention, diagnosis, treatment and care in five years is both audacious and achievable. As the leader of a biotech company that earned FDA approval for an at-home colon cancer screening test, I have seen firsthand how innovation and collaboration among the private sector, government, and research institutions can make a real difference in bringing lifesaving screening tools to market — quickly.
As Vice President Biden said at last week’s Cancer Moonshot Summit, “Prevention can help save a lot more lives than anything else we can do.” This is why expanding access to innovative screening tools is imperative to reaching the Moonshot goal. Read more …
Kevin Conroy is Chairman, President and CEO of Exact Sciences Corp., the Madison-Wisconsin based developer and manufacturer of Cologuard.